Pulmonary Arterial Hypertension Market Size, Share & Trends Analysis Report By Drug Class, By Type (Branded, Generics), By Route of Administration (Oral, Intravenous/Subcutaneous, Inhalational), By Region, And Segment Forecasts, 2025 - 2033
Description
Pulmonary Arterial Hypertension Market Summary
The global pulmonary arterial hypertension market size was estimated at USD 8.02 billion in 2024 and is projected to reach USD 13.34 billion by 2033, growing at a CAGR of 5.9% from 2025 to 2033. The market growth is majorly attributed to increasing support from government & healthcare authorities for new drug development, rising prevalence of pulmonary arterial hypertension, and favorable reimbursement policies.
In addition, substantial research and development activities in the field of pulmonary arterial hypertension are also projected to have a positive impact on the market’s growth. For instance, in December 2023, a group of researchers form Cedars-Sinai revealed that unique-cell based approach is well suited for treatment of pulmonary arterial hypertension. Currently, the study in phase I of clinical trials.
The PAH market thrives on significant investments from industry leaders and governments, targeting the unmet needs of this rare condition. Growth is driven by increasing PAH incidence linked to lifestyle factors such as smoking and HIV, alongside aging populations. Government policies, such as the U.S. Orphan Drug Act, incentivize drug development, boosting market expansion. Enhanced diagnostic capabilities and awareness further accelerate demand for effective therapies.
Prostacyclin and analogs, holding 47.11% of 2024 revenue, remain pivotal, with drugs such as epoprostenol and selexipag offers vasodilation benefits. Their ability to improve pulmonary blood flow and patient quality of life underpins their market leadership. Innovations like oral formulations enhance accessibility, and drive segment growth through improved patient adherence.
Sotatercept (Winrevair) has been FDA approved in March 2024 for the treatment of adults with pulmonary arterial hypertension (PAH). It is the first activin signaling inhibitor approved for PAH, shown to increase exercise capacity, improve WHO functional class, and reduce the risk of clinical worsening events.
Emerging technologies, such as the Remunity Pump launched in 2021, revolutionize drug delivery, offering subcutaneous treprostinil administration. Digital health tools, including wearables, enable real-time monitoring, personalizing PAH management. These advancements, paired with a strong R&D pipeline, promise to reshape treatment paradigms and sustain market momentum through 2033.
Global Pulmonary Arterial Hypertension Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global pulmonary arterial hypertension market report based on drug class, type, route of administration, and region:
The global pulmonary arterial hypertension market size was estimated at USD 8.02 billion in 2024 and is projected to reach USD 13.34 billion by 2033, growing at a CAGR of 5.9% from 2025 to 2033. The market growth is majorly attributed to increasing support from government & healthcare authorities for new drug development, rising prevalence of pulmonary arterial hypertension, and favorable reimbursement policies.
In addition, substantial research and development activities in the field of pulmonary arterial hypertension are also projected to have a positive impact on the market’s growth. For instance, in December 2023, a group of researchers form Cedars-Sinai revealed that unique-cell based approach is well suited for treatment of pulmonary arterial hypertension. Currently, the study in phase I of clinical trials.
The PAH market thrives on significant investments from industry leaders and governments, targeting the unmet needs of this rare condition. Growth is driven by increasing PAH incidence linked to lifestyle factors such as smoking and HIV, alongside aging populations. Government policies, such as the U.S. Orphan Drug Act, incentivize drug development, boosting market expansion. Enhanced diagnostic capabilities and awareness further accelerate demand for effective therapies.
Prostacyclin and analogs, holding 47.11% of 2024 revenue, remain pivotal, with drugs such as epoprostenol and selexipag offers vasodilation benefits. Their ability to improve pulmonary blood flow and patient quality of life underpins their market leadership. Innovations like oral formulations enhance accessibility, and drive segment growth through improved patient adherence.
Sotatercept (Winrevair) has been FDA approved in March 2024 for the treatment of adults with pulmonary arterial hypertension (PAH). It is the first activin signaling inhibitor approved for PAH, shown to increase exercise capacity, improve WHO functional class, and reduce the risk of clinical worsening events.
Emerging technologies, such as the Remunity Pump launched in 2021, revolutionize drug delivery, offering subcutaneous treprostinil administration. Digital health tools, including wearables, enable real-time monitoring, personalizing PAH management. These advancements, paired with a strong R&D pipeline, promise to reshape treatment paradigms and sustain market momentum through 2033.
Global Pulmonary Arterial Hypertension Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global pulmonary arterial hypertension market report based on drug class, type, route of administration, and region:
- Drug Class Outlook (Revenue, USD Million, 2021 - 2033)
- Endothelin Receptor Antagonists (ERAs)
- PDE-5 Inhibitors
- Prostacyclin and Prostacyclin Analogs
- SGC Stimulators
- Type Outlook (Revenue, USD Million, 2021 - 2033)
- Branded
- Generics
- Route of Administration Outlook (Revenue, USD Million, 2021 - 2033)
- Oral
- Intravenous/ subcutaneous
- Inhalational
- Regional Outlook (Revenue, USD Million, 2021 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Sweden
- Denmark
- Norway
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- Thailand
- Latin America
- Brazil
- Argentina
- Rest of LA
- MEA
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Table of Contents
150 Pages
- Chapter 1. Methodology and Scope
- 1.1. Market Segmentation and Scope
- 1.2. Segment Definitions
- 1.2.1. Drug Class
- 1.2.2. By Type
- 1.2.3. Route of Administration
- 1.3. Estimates and Forecast Timeline
- 1.4. Research Methodology
- 1.5. Information Procurement
- 1.5.1. Purchased Database
- 1.5.2. GVR’s Internal Database
- 1.5.3. Secondary Sources
- 1.5.4. Primary Research
- 1.6. Information Analysis
- 1.6.1. Data Analysis Models
- 1.7. Market Formulation & Data Visualization
- 1.8. Model Details
- 1.8.1. Commodity Flow Analysis
- 1.9. List of Secondary Sources
- 1.9.1. Objectives
- Chapter 2. Executive Summary
- 2.1. Market Snapshot
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot
- Chapter 3. Pulmonary Arterial Hypertension Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.2. Market Restraint Analysis
- 3.3. Business Environment Analysis
- 3.3.1. Industry Analysis - Porter’s Five Forces Analysis
- 3.3.1.1. Supplier Power
- 3.3.1.2. Buyer Power
- 3.3.1.3. Substitution Threat
- 3.3.1.4. Threat of New Entrants
- 3.3.1.5. Competitive Rivalry
- 3.3.2. PESTLE Analysis
- 3.3.3. Pipeline Analysis
- 3.3.4. Patent Expiry Analysis
- 3.3.5. Pricing Analysis
- Chapter 4. Pulmonary Arterial Hypertension Market: Drug Class Business Analysis
- 4.1. Drug Class Market Share, 2024 & 2033
- 4.2. Segment Dashboard
- 4.3. Pulmonary Arterial Hypertension Market: Drug Class Movement Analysis, USD Million, 2023 & 2030
- 4.4. Endothelin Receptor Antagonists (ERAs)
- 4.4.1. Endothelin Receptor Antagonists (ERAs) Market, 2021 - 2033 (USD Million)
- 4.5. PDE-5 Inhibitors
- 4.5.1. PDE-5 Inhibitors Market, 2021 - 2033 (USD Million)
- 4.6. Prostacyclin and Prostacyclin Analogs
- 4.6.1. Prostacyclin and Prostacyclin Analogs Market, 2021 - 2033 (USD Million)
- 4.7. SGC Stimulators
- 4.7.1. SGC Stimulators Market, 2021 - 2033 (USD Million)
- Chapter 5. Pulmonary Arterial Hypertension Market: Type Business Analysis
- 5.1. Type Market Share, 2024 & 2033
- 5.2. Pulmonary Arterial Hypertension Market: Type Movement Analysis, USD Million, 2023 & 2030
- 5.3. Branded
- 5.3.1. Branded Market, 2021 - 2033 (USD Million)
- 5.4. Generic
- 5.4.1. Generic Market, 2021 - 2033 (USD Million)
- Chapter 6. Pulmonary Arterial Hypertension Market: Route of Administration Business Analysis
- 6.1. Route of Administration Market Share, 2024 & 2033
- 6.2. Pulmonary Arterial Hypertension Market: Route of Administration Movement Analysis, USD Million, 2023 & 2030
- 6.3. Oral
- 6.3.1. Oral Market, 2021 - 2033 (USD Million)
- 6.4. Intravenous/ Subcutaneous
- 6.4.1. Intravenous/ Subcutaneous Market, 2021 - 2033 (USD Million)
- 6.5. Inhalational
- 6.5.1. Inhalational Market, 2021 - 2033 (USD Million)
- Chapter 7. Regional Business Analysis
- 7.1. Pulmonary Arterial Hypertension Market Share By Region, 2023 & 2030
- 7.2. North America
- 7.2.1. North America Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
- 7.2.2. U.S.
- 7.2.2.1. Key Country Dynamics
- 7.2.2.2. Target Disease Prevalence
- 7.2.2.3. Regulatory Framework
- 7.2.2.4. U.S. Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
- 7.2.3. Canada
- 7.2.3.1. Key Country Dynamics
- 7.2.3.2. Target Disease Prevalence
- 7.2.3.3. Regulatory Framework
- 7.2.3.4. Canada Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
- 7.2.4. Mexico
- 7.2.4.1. Key Country Dynamics
- 7.2.4.2. Target Disease Prevalence
- 7.2.4.3. Regulatory Framework
- 7.2.4.4. Mexico Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
- 7.3. Europe
- 7.3.1. Europe Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
- 7.3.2. UK
- 7.3.2.1. Key Country Dynamics
- 7.3.2.2. Target Disease Prevalence
- 7.3.2.3. Regulatory Framework
- 7.3.2.4. UK Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
- 7.3.3. Germany
- 7.3.3.1. Key Country Dynamics
- 7.3.3.2. Target Disease Prevalence
- 7.3.3.3. Regulatory Framework
- 7.3.3.4. Germany Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
- 7.3.4. France
- 7.3.4.1. Key Country Dynamics
- 7.3.4.2. Target Disease Prevalence
- 7.3.4.3. Regulatory Framework
- 7.3.4.4. France Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
- 7.3.5. Italy
- 7.3.5.1. Key Country Dynamics
- 7.3.5.2. Target Disease Prevalence
- 7.3.5.3. Regulatory Framework
- 7.3.5.4. Italy Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
- 7.3.6. Spain
- 7.3.6.1. Key Country Dynamics
- 7.3.6.2. Target Disease Prevalence
- 7.3.6.3. Regulatory Framework
- 7.3.6.4. Spain Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
- 7.3.7. Sweden
- 7.3.7.1. Key Country Dynamics
- 7.3.7.2. Target Disease Prevalence
- 7.3.7.3. Regulatory Framework
- 7.3.7.4. Sweden Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
- 7.3.8. Norway
- 7.3.8.1. Key Country Dynamics
- 7.3.8.2. Target Disease Prevalence
- 7.3.8.3. Regulatory Framework
- 7.3.8.4. Norway Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
- 7.3.9. Denmark
- 7.3.9.1. Key Country Dynamics
- 7.3.9.2. Target Disease Prevalence
- 7.3.9.3. Regulatory Framework
- 7.3.9.4. Denmark Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
- 7.4. Asia Pacific
- 7.4.1. Asia Pacific Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
- 7.4.2. Japan
- 7.4.2.1. Key Country Dynamics
- 7.4.2.2. Target Disease Prevalence
- 7.4.2.3. Regulatory Framework
- 7.4.2.4. Japan Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
- 7.4.3. China
- 7.4.3.1. Key Country Dynamics
- 7.4.3.2. Target Disease Prevalence
- 7.4.3.3. Regulatory Framework
- 7.4.3.4. China Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
- 7.4.4. India
- 7.4.4.1. Key Country Dynamics
- 7.4.4.2. Target Disease Prevalence
- 7.4.4.3. Regulatory Framework
- 7.4.4.4. India Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
- 7.4.5. Australia
- 7.4.5.1. Key Country Dynamics
- 7.4.5.2. Target Disease Prevalence
- 7.4.5.3. Regulatory Framework
- 7.4.5.4. Australia Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
- 7.4.6. Thailand
- 7.4.6.1. Key Country Dynamics
- 7.4.6.2. Target Disease Prevalence
- 7.4.6.3. Regulatory Framework
- 7.4.6.4. Thailand Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
- 7.4.7. South Korea
- 7.4.7.1. Key Country Dynamics
- 7.4.7.2. Target Disease Prevalence
- 7.4.7.3. Regulatory Framework
- 7.4.7.4. South Korea Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
- 7.5. Latin America
- 7.5.1. Latin America Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
- 7.5.2. Brazil
- 7.5.2.1. Key Country Dynamics
- 7.5.2.2. Target Disease Prevalence
- 7.5.2.3. Regulatory Framework
- 7.5.2.4. Brazil Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
- 7.5.3. Argentina
- 7.5.3.1. Key Country Dynamics
- 7.5.3.2. Target Disease Prevalence
- 7.5.3.3. Regulatory Framework
- 7.5.3.4. ArgentinaPulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
- 7.5.4. Rest of LATAM
- 7.5.4.1. Key Country Dynamics
- 7.5.4.2. Target Disease Prevalence
- 7.5.4.3. Regulatory Framework
- 7.5.4.4. Rest of LATAM Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
- 7.6. MEA
- 7.6.1. MEA Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
- 7.6.2. South Africa
- 7.6.2.1. Key Country Dynamics
- 7.6.2.2. Target Disease Prevalence
- 7.6.2.3. Regulatory Framework
- 7.6.2.4. South Africa Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
- 7.6.3. Saudi Arabia
- 7.6.3.1. Key Country Dynamics
- 7.6.3.2. Target Disease Prevalence
- 7.6.3.3. Regulatory Framework
- 7.6.3.4. Saudi Arabia Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
- 7.6.4. UAE
- 7.6.4.1. Key Country Dynamics
- 7.6.4.2. Target Disease Prevalence
- 7.6.4.3. Regulatory Framework
- 7.6.4.4. UAE Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
- 7.6.5. Kuwait
- 7.6.5.1. Key Country Dynamics
- 7.6.5.2. Target Disease Prevalence
- 7.6.5.3. Regulatory Framework
- 7.6.5.4. Kuwait Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
- Chapter 8. Competitive Landscape
- 8.1. Company Categorization
- 8.2. Strategy Mapping
- 8.3. Company Market Share Analysis, 2023
- 8.4. Company Profiles/Listing
- 8.4.1. United Therapeutics Corporation
- 8.4.1.1. Overview
- 8.4.1.2. Financial Performance
- 8.4.1.3. Product Benchmarking
- 8.4.1.4. Strategic Initiatives
- 8.4.2. Johnson & Johnson Services Inc.
- 8.4.2.1. Overview
- 8.4.2.2. Financial Performance
- 8.4.2.3. Product Benchmarking
- 8.4.2.4. Strategic Initiatives
- 8.4.3. Bayer AG
- 8.4.3.1. Overview
- 8.4.3.2. Financial Performance
- 8.4.3.3. Product Benchmarking
- 8.4.3.4. Strategic Initiatives
- 8.4.4. Gilead Sciences, Inc.
- 8.4.4.1. Overview
- 8.4.4.2. Financial Performance
- 8.4.4.3. Product Benchmarking
- 8.4.4.4. Strategic Initiatives
- 8.4.5. Viatris Inc.
- 8.4.5.1. Overview
- 8.4.5.2. Financial Performance
- 8.4.5.3. Product Benchmarking
- 8.4.5.4. Strategic Initiatives
- 8.4.6. GlaxoSmithKline
- 8.4.6.1. Overview
- 8.4.6.2. Financial Performance
- 8.4.6.3. Product Benchmarking
- 8.4.6.4. Strategic Initiatives
- 8.4.7. Novartis AG
- 8.4.7.1. Overview
- 8.4.7.2. Financial Performance
- 8.4.7.3. Product Benchmarking
- 8.4.7.4. Strategic Initiatives
- 8.4.8. Lupin Pharmaceuticals Inc.
- 8.4.8.1. Overview
- 8.4.8.2. Financial Performance
- 8.4.8.3. Product Benchmarking
- 8.4.8.4. Strategic Initiatives
- 8.4.9. Sun Pharmaceutical Industries, Inc.
- 8.4.9.1. Overview
- 8.4.9.2. Financial Performance
- 8.4.9.3. Product Benchmarking
- 8.4.9.4. Strategic Initiatives
- 8.4.10. Teva Pharmaceuticals Industries Ltd.
- 8.4.10.1. Overview
- 8.4.10.2. Financial Performance
- 8.4.10.3. Product Benchmarking
- 8.4.10.4. Strategic Initiatives
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.